Radiomics is leading a clinical trial entitled "SALMON" ("meaSure lung cAncer bioLogy and treatMent respOnse via imagiNg"), a prospective, interventional, multi-center, multi-country, biomarker validation study, involving 30 healthcare institutions within the EU, to demonstrate the value of AI solutions in 1000 patients with non-small cell lung cancer.
onetrial, two tracks, multiplevaluable solutions
This study has received funding from SPW and DG06
![[:swvar:ufile:1:description:]](/swfiles/files/logo-radiomics.svg?nc=1651654544){kind=logo}